Muscular Dystrophy Association Launches ALS Awareness Month with Public Service Announcement ‘Answering the Call’
29 avr. 2024 09h00 HE
|
Muscular Dystrophy Association
New York, April 29, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced programming and fundraising events in support of people living with Amyotrophic Lateral...
Muscular Dystrophy Association Launches ‘Access The Vote’ Campaign to Amplify Rights of Accessible Voting
23 avr. 2024 08h49 HE
|
Muscular Dystrophy Association
Washington, D.C., April 23, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) is proud to announce the launch of its latest MDA Advocacy initiative, the ‘Access The Vote’ Campaign,...
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
28 mars 2024 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Burn Boot Camp and Muscular Dystrophy Association Team Up for 8th Annual 'Be Their Muscle' Philanthropic Event
25 mars 2024 09h49 HE
|
Muscular Dystrophy Association
Charlotte, North Carolina, March 25, 2024 (GLOBE NEWSWIRE) -- Burn Boot Camp, a leading boutique fitness franchise, has teamed up with the Muscular Dystrophy Association (MDA) for its eighth annual...
NFL Running Back Nyheim Hines Supports Nation's Largest St. Patrick’s Day Fundraising Campaign to Benefit Muscular Dystrophy Association
13 mars 2024 09h00 HE
|
Muscular Dystrophy Association
New York, March 13, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced its continued partnership with Nyheim Hines -- an NFL running back who has agreed to a new...
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
13 mars 2024 07h55 HE
|
Catalyst Pharmaceuticals, Inc.
AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for...
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
27 févr. 2024 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Brooke Eby, ALS Patient and Advocate, to deliver Keynote Address at 2024 MDA Clinical & Scientific Conference
15 févr. 2024 09h00 HE
|
Muscular Dystrophy Association
New York, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Brooke Eby will be the keynote speaker at the 2024 MDA Clinical & Scientific...
Muscular Dystrophy Association Opens Registration for Campers and Volunteers for MDA Summer Camp 2024 to be Held at Locations Nationwide
22 janv. 2024 09h00 HE
|
Muscular Dystrophy Association
New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the opening of registration for both campers and volunteers for its MDA Summer Camp program. MDA...
Muscular Dystrophy Association Announces Acosta Group’s Historic $100 Million Fundraising Milestone
21 déc. 2023 09h00 HE
|
Muscular Dystrophy Association
New York, Dec. 21, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today that long-term partner Acosta Group has reached a historic $100 million milestone in fundraising...